Scientists at Scripps Research Institute developed a method to modify organic molecules, expanding possibilities for new pharmaceuticals and improving old ones. The innovation makes it easier to attach biologically active functional groups to drug molecules.
Researchers at Scripps Research Institute and Vanderbilt University have created the most detailed 3-D picture yet of a membrane protein linked to learning, memory, anxiety, pain and brain disorders. The study focused on the mGlu1 receptor, which helps regulate neurotransmitter glutamate.
Scientists at Scripps Research Institute develop new probes to detect functional, normally folded, and disease-associated misfolded conformations of proteins in cells. The technology paves the way for discovering new drugs for misfolding diseases such as Alzheimer's and Parkinson's.
Researchers at The Scripps Research Institute have mapped the severe immune overreaction known as a cytokine storm in flu virus infections. The study found that a potent new class of anti-inflammatory compounds can quiet this reaction, allowing infected hosts to mount an effective immune response.
Researchers have identified a self-resistance mechanism in Streptomyces platensis bacteria that can bypass antibiotic fatty acid synthesis inhibition. This discovery could lead to the development of new, potent antibiotic drug candidates.
Scientists from the Scripps Research Institute will investigate axonal transport, a cellular process crucial for signaling and long-term memory storage. The goal is to identify molecular regulators of axonal transport to develop new approaches for treating memory disorders.
Researchers at Scripps Research Institute create Inforna, a technique to identify potent compounds targeting cancer-causing microRNAs. The method enables unprecedented targeting of disease-associated RNAs, offering a promising approach to designing novel anti-cancer drugs.
Researchers at The Scripps Research Institute found a protein, Protein M, that attaches to antibodies and prevents them from binding to their target, helping bacteria evade the immune response. This discovery could lead to new antibacterial therapies and tools for research and drug development.
Researchers at Scripps Research Institute developed a new method to design artificial proteins that can stimulate the production of virus-neutralizing antibodies. The approach was tested on a candidate vaccine against respiratory syncytial virus (RSV), showing promise in rhesus macaques.
Researchers at TSRI will explore Notch signaling pathways as therapeutic options for non-small cell lung cancer. The grant aims to improve treatment outcomes for advanced disease, where survival rates remain poor despite falling death rates.
Chi-Huey Wong, a professor of chemistry at The Scripps Research Institute, has been awarded the 2014 Wolf Prize in Chemistry for his groundbreaking work on synthesizing complex carbohydrates and glycoproteins. His research methods have led to breakthroughs in understanding cancer progression and developing vaccines and therapeutics.
Researchers identified a critical regulator of BACE1, an enzyme involved in Alzheimer's disease pathology. The study found that levels of this regulating protein, Rheb, are decreased in the brains of Alzheimer's patients and may be a significant factor in disease progression.
Researchers at Scripps Florida Institute discovered significant changes in gene expression and neural circuitry as neurons age, shedding light on cognitive decline and potential therapeutic targets. The study, using the marine snail Aplysia californica, highlights the complex interplay between aging and neuron communication.
Researchers at Scripps Research Institute develop new drug discovery technique to quickly and cheaply identify antibodies that protect human cells from viral infections. The technique successfully identifies two antibodies that prevent cold virus-induced cell death, highlighting its potential for treating various diseases.
Researchers at Scripps Research Institute describe two new drug scaffolds that target the kappa opioid receptor, offering novel tools for treating pain, addiction, and other disorders. The compounds, called biased agonists, activate the receptor without recruiting beta arrestin, a molecule associated with depression.
Researchers discovered how sodium controls opioid receptors, a major class of brain cell receptors. The findings suggest new therapeutic approaches to treat pain and mood disorders. Sodium's effect on receptor activity is crucial for developing better opioid-receptor-targeting drugs.
Researchers developed a test to predict early onset of heart attacks by identifying circulating endothelial cells (CECs) in the blood. The technique has been successful in distinguishing patients undergoing treatment for a recent heart attack with healthy controls.
Researchers found that a subset of immune cells expresses the multidrug transporter MDR1 and are linked to inflammation in Crohn's patients. These cells may play a major role in the development of steroid resistance, suggesting that steroid treatment itself may be responsible for their accumulation.
Researchers have confirmed the importance of the nociceptin system in modulating the effects of stress. The study found that this system can prevent and even reverse some cellular effects of acute stress in an animal model.
Researchers at Scripps Research Institute have discovered the atomic-level structure of a genetic defect causing myotonic dystrophy type 2, allowing them to design compounds that improve disease-associated defects in treated cells. The study's findings hold promise for treating this rare form of muscular dystrophy.
The new strategy enables rapid selection of chemical compounds with a desired effect on cells and highlights the underlying biological mechanisms. Researchers identified a compound, WWL113, that shows promise for treating obesity-linked diabetes and also inhibits a previously untargeted enzyme, Ces3.
Researchers at Scripps Research Institute have developed a new method to map the 3D structure of membrane proteins, including the human serotonin receptor. This approach enables faster and more accurate imaging, potentially condensing the timeline for structural studies from months to days.
Researchers at Scripps Florida Institute developed a compound that dramatically reduces joint inflammation in animal models of rheumatoid arthritis. The study showed the compound, SR2211, blocked symptoms and bone erosion in mice within eight to ten days of treatment.
A recent study by TSRI scientists has found that the emerging bird flu strain H7N9 is still mainly adapted for infecting birds, not humans. The researchers analyzed virus samples from the Chinese outbreak and found that H7N9 viruses do not yet seem well adapted for binding to human receptors.
Researchers at Scripps Research Institute have discovered a natural mechanism that cells use to protect mitochondria from damage, a key factor in neurodegenerative disorders and cancer. The study reveals that reducing the import of proteins into mitochondria can help protect these organelles during stress.
Researchers have determined the high-resolution atomic structure of E2 envelope glycoprotein, a crucial part of the hepatitis C virus. The new data reveal unexpected structural features and should greatly speed efforts to make an effective hepatitis C vaccine.
Scientists have solved the structure of a key protein in the Nipah virus, which could lead to the development of an antiviral drug. The discovery was made by a team at the Scripps Research Institute and found similarities with measles and mumps viruses.
A clinical trial found gabapentin to be safe and effective in treating alcohol dependence, reducing cravings, depression, and sleeplessness. The drug's effect on drinking outcomes was at least as large as existing FDA-approved treatments, with significant benefits seen in patients who received the high-dose regimen.
Researchers have determined the atomic-level structure of the tripartite HIV envelope protein, a complex target for vaccines. The findings provide insights into the process by which the Env trimer assembles and undergoes shape changes during infection.
Researchers at Scripps Research Institute have developed a promising technique for treating human eye disease by targeting microRNAs, which can stop abnormal blood vessel growth. The approach shows promise in preventing blindness in diseases like neovascular macular degeneration and diabetic retinopathy.
Researchers found a brain-to-body signaling circuit in roundworms that enables weight loss independently of food intake, involving serotonin and octopamine neurotransmitters. The discovery hints at a similar circuit in humans and other mammals, potentially leading to more potent weight-loss therapies combining serotonin and adrenaline.
Researchers at Scripps Research Institute have identified key signaling proteins that contribute to the development of inflammatory diseases such as rheumatoid arthritis and psoriasis. By targeting these proteins, a new class of anti-inflammatory therapy may be developed.
Scientists have identified a new approach to treating multiple sclerosis by boosting oligodendrocyte precursor cells, which can repair damaged nerve fibers. A Parkinson's disease drug called benztropine was highly effective in treating a standard model of MS in mice, both alone and in combination with existing therapies.
Chemists at Scripps Research Institute develop new technique to create more stable antibody-drug conjugates, reducing toxicity and increasing efficacy. The new method uses a novel Thiol-Click reaction to form stronger linkages with cysteine amino acids.
Researchers have identified a potential new drug for an inherited form of cancer with no known cure. The new compound, FRAX97, targets a protein family that plays a critical role in the development of Neurofibromatosis type 2. By inhibiting these kinases, tumor growth can be slowed and progression reduced by over 80%.
Researchers identified the subunit where binding took place and showed that a known activator fully activates AMPK through biochemical communication with other subunits. This discovery confirms the activation site and enables the modeling of potential drugs.
Researchers at Scripps Florida Institute have developed a highly programmable platform for creating synthetic cellular structures with complex membrane compositions. The approach enables the assembly of multi-layered membranes resembling the cell nucleus envelope, offering new insights into biological function and evolution.
Scientists at Scripps Research Institute have created a comprehensive roadmap of the protein interactions that enable cells in the pancreas to produce, store and secrete insulin. The finding makes possible a deeper scientific understanding of the insulin secretion process and how it fails in insulin disorders such as type 2 diabetes.
Researchers at Scripps Research Institute discovered that an essential protein evolved chiefly by changing its movement, rather than structure. This finding has implications for designing more effective antibiotics and drugs targeting the protein dihydrofolate reductase.
Scott Hansen, a Scripps Research Institute scientist, has won the NIH New Innovator Award to study mechanosensation, particularly touch and hearing. The award provides $2.8 million in research funding over five years to explore the molecular mechanisms behind sensing touch.
Researchers found that essential proteins evolve chiefly by changing how they move, rather than their molecular structure. This discovery has significant implications for the design of antibiotics and other drugs targeting dihydrofolate reductase.
Researchers at Scripps Research Institute have developed a new method, called Extensive Combinatorial Refinement (ExCoR), that combines existing formulas to create more accurate computer models of molecules. This process can help identify the best algorithms for refining structural details and improve the development of drug candidates.
Researchers at Scripps Research Institute discovered a critical role of dendritic epidermal T cells in producing interleukin-17A to promote wound healing. The study found that these skin-resident immune cells function as 'first responders' to skin injuries by producing IL-17A, which wards off infection and promotes wound healing.
Researchers at Scripps Research Institute discovered that an antibody binding to HIV likely targets the body's own proteins, complicating its development as a vaccine. The finding raises concerns about potential autoimmune diseases and self-reactivity in 4E10 antibodies.
Researchers at Scripps Research Institute developed new compounds that show 10-200 times greater potency than vinblastine and overcome drug resistance. These improvements aim to boost the effectiveness of vincristine against childhood leukemias and Hodgkin's disease.
Researchers have determined the high-resolution atomic structure of a cell-surface receptor used by most strains of HIV to infect human immune cells. The study provides detailed insights into how HIV attaches to cells and blocks its entry, guiding the development of next-generation drugs.
Researchers found a group of Wnt proteins essential for long-term memory, but not short-term memory. The study suggests that Wnt signaling participates actively in memory formation and shares molecular mechanisms with early development.
Chemists at Scripps Research Institute have found a way to apply the SN2 reaction to a stubborn class of chemicals, enabling the synthesis of promising antimalarial and anticancer compounds that were previously off limits. The new method uses a special acid catalyst and nitrogen-containing molecule to complete stereoinversion reactions.
A large DNA-sequencing study of anorexia nervosa has linked the eating disorder to variants in a gene coding for an enzyme regulating cholesterol metabolism. This finding suggests that anorexia could be caused by disruption in normal cholesterol processing, affecting mood and eating behavior.
Researchers at Scripps Research Institute successfully erased dangerous drug-associated memories in mice and rats without affecting other memories. The study's findings suggest a clear method to disrupt unwanted memories while leaving benign ones intact.